Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
- PMID: 3798106
- DOI: 10.1126/science.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Abstract
The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Similar articles
-
neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.J Clin Oncol. 1998 Apr;16(4):1340-9. doi: 10.1200/JCO.1998.16.4.1340. J Clin Oncol. 1998. PMID: 9552035
-
The association of HER-2/neu amplification with breast cancer recurrence.Arch Surg. 2000 Dec;135(12):1469-74. doi: 10.1001/archsurg.135.12.1469. Arch Surg. 2000. PMID: 11115354
-
HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.Anticancer Res. 1992 Mar-Apr;12(2):419-25. Anticancer Res. 1992. PMID: 1349794
-
Follow-up study of HER-2/neu amplification in primary breast cancer.Cancer Res. 1991 Feb 1;51(3):944-8. Cancer Res. 1991. PMID: 1988136 Review.
-
The significance of oncogene amplification in primary breast cancer.Int J Cancer. 1989 Feb 15;43(2):270-2. doi: 10.1002/ijc.2910430218. Int J Cancer. 1989. PMID: 2563720 Review.
Cited by
-
Cancer Immunoprevention: Current Status and Future Directions.Arch Immunol Ther Exp (Warsz). 2021 Feb 27;69(1):3. doi: 10.1007/s00005-021-00604-x. Arch Immunol Ther Exp (Warsz). 2021. PMID: 33638703 Review.
-
Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study.Oncologist. 2013;18(7):795-801. doi: 10.1634/theoncologist.2013-0065. Epub 2013 Jul 3. Oncologist. 2013. PMID: 23823908 Free PMC article.
-
Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer.J Cancer Res Clin Oncol. 2013 Mar;139(3):491-8. doi: 10.1007/s00432-012-1355-3. Epub 2012 Nov 23. J Cancer Res Clin Oncol. 2013. PMID: 23180020
-
Integration of artificial intelligence and precision oncology in Latin America.Front Med Technol. 2022 Oct 13;4:1007822. doi: 10.3389/fmedt.2022.1007822. eCollection 2022. Front Med Technol. 2022. PMID: 36311461 Free PMC article. Review.
-
Particle shape enhances specificity of antibody-displaying nanoparticles.Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3270-5. doi: 10.1073/pnas.1216893110. Epub 2013 Feb 11. Proc Natl Acad Sci U S A. 2013. PMID: 23401509 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
